WASHINGTON, May 18 - President Donald Trump is preparing to announce a significant enlargement of TrumpRx.gov, the government-supported online portal that provides discounted prescription medications under his administration's pricing arrangement, a White House official said.
The administration plans to add generic medicines to the site, and billionaire Mark Cuban is scheduled to attend the White House event. Cuban operates an online pharmacy, Cost Plus Drugs, through which he sells discounted medicines directly to consumers.
TrumpRx was launched in January as part of the administration's most-favored-nation agreements with pharmaceutical manufacturers, a policy effort intended to lower the cost of prescription drugs by tying U.S. prices to those observed in other developed countries. President Trump has publicly pledged to make prescription drugs less expensive for Americans than anywhere else in the world.
However, a comparison of publicly available prices found that the prices listed on the website are not lower than those paid in the United Kingdom. That comparison calls into question whether the current listings meet the stated aim of producing prices cheaper than those found overseas.
Context and implications
The move to include generics on TrumpRx.gov represents an effort to expand the range of medicines available through the program. The participation of an entrepreneur who operates a direct-to-consumer discounted pharmacy underscores private-public intersections in the rollout of the expanded offering.
How the expanded list of generics will affect consumer out-of-pocket costs, market pricing dynamics, or relationships with drugmakers is not detailed in the administration's announcement. The comparison showing prices on the site are not lower than U.K. prices is based on publicly available price data.
Key points
- Trump will announce an expansion of TrumpRx.gov, with generics being added to the program.
- Mark Cuban, who runs a discounted online pharmacy called Cost Plus Drugs, is expected to attend the White House event.
- TrumpRx, launched in January as part of most-favored-nation pricing deals, aims to lower U.S. prescription drug prices; current publicly available comparisons show site prices are not lower than U.K. prices.
Risks and uncertainties
- Prices listed on TrumpRx.gov are not lower than those paid in the United Kingdom, challenging the administration's stated pledge on global price leadership.
- The announcement does not specify how adding generics will translate into lower consumer costs or how it will interact with drugmakers' pricing strategies.
- The extent of the program's market impact and consumer uptake remains unclear based on the information provided in the announcement.